Automation cuts prostate cancer drug candidate production from 6 hours to 38 minutes

A proof-of-concept study has created a blueprint for producing prostate cancer treatment more efficiently. Researchers at the University of Missouri, Cancer Targeted Technology (CTT) and Isotherapeutics Group (ITG) discovered an innovative method to speed production of a cancer-fighting drug candidate. The breakthrough means the prostate cancer drug candidate, known as CTT1403, could be produced more efficiently and reliably, and could lead to the production of more doses for larger clinical trials.